| Patients with paroxysmal nocturnal hemoglobinuria demonstrate a prothrombotic clotting phenotype which is improved by complement inhibition with eculizumab |
|
American Journal of Hematology |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Safety and activity of selinexor in patients with myelodysplastic syndromes or oligoblastic acute myeloid leukaemia refractory to hypomethylating agents: a single-centre, single-arm, phase 2 trial |
|
Lancet Hematology |
Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS) |
| Letter to the Editor: Allogeneic hematopoietic stem cell transplantation in elderly patients with acute myeloid leukemia or myelodysplastic syndromes: myth and reality |
|
Leukemia |
Myelodysplastic Syndromes (MDS) |
| TP53 mutations in myelodysplastic syndromes and secondary AML confer an immunosuppressive phenotype |
|
Blood |
Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS) |
| Prognostic significance of serial molecular annotation in myelodysplastic syndromes (MDS) and secondary acute myeloid leukemia (sAML) |
|
Leukemia |
Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS) |
| HDAC4 inhibition disrupts TET2 function in high-risk MDS and AML |
|
Aging |
Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS) |
| Chronic fatigue in myelodysplastic syndromes: Looking beyond anemia |
|
Critical reviews in hematology/oncology |
Myelodysplastic Syndromes (MDS) |
| Eat and be healthy: nutritional status in myelodysplastic syndromes |
|
Leukemia & Lymphoma |
Myelodysplastic Syndromes (MDS) |
| Consensus minimum hemoglobin level above which patients with myelodysplastic syndromes can safely forgo transfusions |
|
Leukemia & Lymphoma |
Myelodysplastic Syndromes (MDS) |
| Patient and physician perceptions about blood transfusions in the myelodysplastic syndromes |
|
Leukemia Research |
Myelodysplastic Syndromes (MDS) |
